Peter L Greenberg, MD
Hematology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 5
- 2 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
5 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Greenberg’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
5 of 5 plans
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence G14630 · Current
Licensed to practise in California · since 1968 · expires 2027-11-30 · George Washington University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$18,606
Medicare paid this office $18,606 for 82 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Telephone medical discussion with physician, 21-30 minutes | 59 | $13,426 | $119 |
| New patient visit (60+ min) | 19 | $3,966 | $209 |
Who their Medicare patients are
82 Original Medicare patients in 2024. Average age 77 · Women 44% · Health risk score 2.97. Above the middle of the specialty; the typical hematology clinician is at 2.35.
Conditions among them: High blood pressure 72% · Coronary heart disease 39% · Chronic kidney disease 38% · Diabetes 33% · Cancer 26% · Depression 23% · Atrial fibrillation 22% · Heart failure 20% · COPD 16%.
The office billed $70,653, Medicare allowed $24,046 and paid $18,606; for 144 services of 5 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 82 | 144 | 77 | 2.97 | $70,653 | $18,606 |
| 2023 | 80 | 143 | 76 | 2.31 | $95,338 | $14,052 |
| 2022 | 67 | 130 | 76 | 2.35 | $97,243 | $12,990 |
| 2021 | 60 | 117 | 75 | 2.58 | $83,931 | $11,733 |
| 2020 | 65 | 105 | 76 | 2.49 | $51,542 | $9,146 |
| 2019 | 77 | 132 | 76 | 2.76 | $19,049 | $10,677 |
| 2018 | 69 | 132 | 75 | 3.18 | $15,094 | $10,001 |
| 2017 | 82 | 156 | 76 | 2.50 | $33,647 | $13,242 |
| 2016 | 75 | 122 | 76 | 2.52 | $32,044 | $10,435 |
| 2015 | 61 | 107 | 76 | 2.22 | $26,787 | $9,117 |
| 2014 | 69 | 135 | 75 | 2.51 | $31,645 | $10,181 |
| 2013 | 74 | 113 | 76 | 2.68 | $30,740 | $9,892 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 4 services
| New patient visit (60+ min) | 36 | $5,794 | $161 |
| Return visit (30+ min) | 31 | $3,877 | $86 |
| Telephone medical discussion with physician, 21-30 minutes | 26 | $2,432 | $90 |
| Short return visit (20+ min) | 25 | $1,647 | $53 |
2022: 3 services
| Return visit (30+ min) | 30 | $6,016 | $88 |
| New patient visit (60+ min) | 34 | $5,502 | $162 |
| Short return visit (20+ min) | 19 | $1,166 | $47 |
2021: 4 services
| Return visit (30+ min) | 34 | $5,727 | $92 |
| New patient visit (60+ min) | 20 | $3,274 | $164 |
| Long return visit (40+ min) | 11 | $1,389 | $126 |
| Short return visit (20+ min) | 18 | $1,343 | $58 |
2020: 3 services
| New patient visit (60+ min) | 23 | $3,552 | $154 |
| Return visit (30+ min) | 26 | $2,725 | $70 |
| Short return visit (20+ min) | 15 | $953 | $41 |
2019: 3 services
| New patient visit (60+ min) | 34 | $4,534 | $133 |
| Return visit (30+ min) | 33 | $3,461 | $65 |
| Short return visit (20+ min) | 19 | $1,486 | $46 |
2018: 3 services
| New patient visit (60+ min) | 33 | $4,699 | $142 |
| Return visit (30+ min) | 25 | $3,027 | $64 |
| Short return visit (20+ min) | 21 | $1,722 | $38 |
2017: 3 services
| New patient visit (60+ min) | 47 | $6,566 | $140 |
| Return visit (30+ min) | 30 | $3,880 | $66 |
| Short return visit (20+ min) | 19 | $1,506 | $43 |
2016: 2 services
| New patient visit (60+ min) | 30 | $4,272 | $142 |
| Return visit (30+ min) | 38 | $3,844 | $64 |
2015: 3 services
| New patient visit (60+ min) | 30 | $4,443 | $148 |
| Return visit (30+ min) | 25 | $2,977 | $68 |
| Short return visit (20+ min) | 15 | $991 | $38 |
2014: 3 services
| New patient visit (60+ min) | 30 | $4,300 | $143 |
| Return visit (30+ min) | 32 | $3,552 | $65 |
| Short return visit (20+ min) | 22 | $1,911 | $44 |
2013: 3 services
| New patient visit (60+ min) | 37 | $5,249 | $142 |
| Return visit (30+ min) | 32 | $2,988 | $68 |
| Short return visit (20+ min) | 19 | $794 | $38 |
Money from drug and device companies
$16 in 2025
| 2025 | 1 | 1 | None | $16 |
| 2024 | 1 | 1 | None | $21 |
| 2021 | 2 | 2 | $3,000 | $3,023 |
| 2020 | 2 | 2 | $5,020 | $5,020 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Sumitomo Pharma America | Orgovyx | $16 | 1 payment
|
See the published payment
| Sumitomo Pharma America | Meals · 2025-01-07 | Orgovyx | $16 |
See earlier years (2024, 2021, 2020)
2024: $21
| Telix Pharmaceuticals | Illuccix | $21 | 1 payment
|
2021: $3,023
| Novartis Pharmaceuticals | None | $3,000 | 1 payment
|
| Blue Earth Diagnostics | Axumin | $23 | 1 payment
|
2020: $5,020
| Gilead Sciences | None | $2,770 | 1 payment
|
| Celgene | Onureg | $2,250 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Celgene Corporation · Development of A Molecular Ipss for Mds · 2020 | Their institution | $241,794 |
| Gilead Sciences, Inc. · A Randomized, Double-Blind, Multicenter Study Comparing Magrolimab in Combination With Azacitidine Versus Azacitidine Plus Placebo in Treatment-Naive Patients With Higher Risk Myelodysplastic Syndrome · 2021 | Their institution | $231,317 |
| Novartis Pharmaceuticals Corporation · A Phase 1b, Open Label, Multi-Center, Dose Optimization and Dose Expansion Study To Assess the Safety and Efficacy of Dfv890 in Adult Patients With Myeloid Diseases · 2024 | Their institution | $177,687 |
| Celgene Corporation · A Study of Luspatercept (Ace-536) To Treat Anemia Due To Very Low, Low, Or Intermediate Risk Myelodysplastic Syndromes (Medalist) (Ace-536-Mds-001) · 2019 | Their institution | $112,020 |
| Novartis Pharmaceuticals Corporation · A Phase 1b, Open Label, Multi-Center, Dose Optimization and Dose Expansion Study To Assess the Safety and Efficacy of Dfv890 in Adult Patients With Myeloid Diseases · 2023 | Their institution | $69,307 |
| Genentech, Inc. · Ph Ib Combination Study in Mds With Azacitidine Apdl1 · 2020 | Their institution | $64,842 |
| Genentech, Inc. · Ph Ib Combination Study in Mds With Azacitidine Apdl1 · 2019 | Their institution | $54,212 |
| Celgene Corporation · A Phase 3, Double-Blind, Randomized Study To Compa · 2021 | Their institution | $40,542 |
| Celgene Corporation · A Study of Luspatercept (Ace-536) To Treat Anemia Due To Very Low, Low, Or Intermediate Risk Myelodysplastic Syndromes (Medalist) · 2020 | Their institution | $25,838 |
| Novartis Pharmaceuticals Corporation · A Phase 1b, Open Label, Multi-Center, Dose Optimization and Dose Expansion Study To Assess the Safety and Efficacy of Dfv890 in Adult Patients With Myeloid Diseases · 2025 | Their institution | $22,485 |
| Celgene Corporation · Development of A Molecular Ipss for Mds (Na-Ni-Mdsaml-Pi-12799) · 2019 | Their institution | $16,959 |
| Celgene Corporation · A Phase 3b, Open-Label, Single-Arm, Rollover Study To Evaluate Long-Term Safety in Subjects Who Have Participated in Other Luspatercept (Ace-536) Clinical Trials · 2020 | Their institution | $13,864 |
| Celgene Corporation · A Study of Luspatercept (Ace-536) To Treat Anemia Due To Very Low, Low, Or Intermediate Risk Myelodysplastic Syndromes (Medalist) (Ace-536-Mds-001) · 2019 | This clinician | $4,010 |
| Celgene Corporation · A Phase 3b, Open Label, Single-Arm Rollover Study · 2021 | Their institution | $2,939 |
| Celgene Corporation · Phase Iiib Reblozyl Rollover - A Phase 3b, Open Label, Single-Arm Rollover Study To Evaluate Long Term Safety in Subjects Who Have Participated in Other Luspatercept (Ace-536) Clinical Trials. · 2023 | Their institution | $1,200 |
| Novartis Pharmaceuticals Corporation · A Multi Center Randomized Double Blind Placebocontrolled Clinical Trial of Deferasirox in Patients With Myelodysplastic Syndromes Low Int1 Risk and Transfusional Iron Overload Telesto · 2020 | Their institution | $938 |
| Novartis Pharmaceuticals Corporation · A Multi Center Randomized Double Blind Placebocontrolled Clinical Trial of Deferasirox in Patients With Myelodysplastic Syndromes Low Int1 Risk and Transfusional Iron Overload Telesto · 2019 | Their institution | $750 |
| Celgene Corporation · A Phase 3b, Open Label, Single-Arm Rollover Study - A Phase 3b, Open Label, Single-Arm Rollover Study To Evaluate Long Term Safety in Subjects Who Have Participated in Other Luspatercept (Ace-536) Clinical Trials. · 2022 | Their institution | $466 |
| Novartis Pharmaceuticals Corporation · A Randomized, Double-Blind, Placebo-Controlled Phase III Multi-Center Study of Azacitidine With Or Without Mbg453 for the Treatment of Patients With Intermediate, High Or Very High Risk Myelodysplastic Syndrome (Mds) As Per Ipss-R, Or Chronic Myelomonocytic Leukemia-2 (Cmml-2) · 2021 | Their institution | $230 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1912033978
- Licence
- CA G14630California G14630: Current · expires 2027-11-30
- Trained
- George Washington University School of Medicine, 1963
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 207RH0000X (207RH0000X); Internal medicine (207R00000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2007-02-26
- NPI last updated
- 2024-04-26
- NPI record certified
- 2024-04-26
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 875 Blake Wilbur Drive, Stanford, CA, 94305 · 120 Ware Rd, Woodside, CA, 94062